This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Acute and Maintenance Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Acute Schizophrenia: A Post Hoc Analysis
Author(s):

Roger S. McIntyre,1 Desiree M. Matthews,2 Marni E. Harris,3 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

1 Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; 2 Different Mental Health, Charlotte, NC, USA; 3 Alkermes, Inc., Waltham, MA, USA; 4 Alkermes Pharma Ireland Ltd., Dublin, Ireland; 5 Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY, USA; 6 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine Hempstead, Hempstead, NY, USA; 7 Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany

Content available until 10/29/2026